Business Context and Reporting Period
This Form 6-K filing by OKYO Pharma Ltd (the "Company") is dated December 3, 2025. The report serves to disclose a specific corporate event regarding insider share acquisition rather than providing periodic financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure of a securities transaction and does not contain financial statements or performance metrics.
Material Changes
The primary material change disclosed is an increase in the beneficial ownership of the Company's Executive Chairman, Gabriele Cerrone. Through Panetta Partners Limited, an entity in which he holds a beneficial interest, Mr. Cerrone acquired 27,051 ordinary shares on the NASDAQ. This transaction brings his total holding to 10,491,746 shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document explicitly states that the attached news announcement (Exhibit 99.1) is furnished and not deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Insider Ownership: Verify the updated total shareholding of Executive Chairman Gabriele Cerrone (10,491,746 shares).
- Transaction Details: Confirm the acquisition of 27,051 shares via Panetta Partners Limited on the NASDAQ.
- Financial Data: Note that this filing does not contain financial performance data; refer to the most recent Form 20-F for financial metrics.